Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.69 |
| ▸ | CTSS | P25774 | 4/20 | 0.43 |
| ▸ | CTSK | P43235 | 2/20 | 0.42 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1751139 | 0.99 | L3MBTL1 (0.71) | L3MBTL1CTSSCTSKCTSLCTSB | |
| SCHEMBL1750395 | 0.96 | L3MBTL1 (0.67) | L3MBTL1CTSSCTSKCTSLCTSB | |
| SCHEMBL9327072 | 0.94 | L3MBTL1 (0.62) | L3MBTL1CTSSCTSKCTSLCTSB | |
| SCHEMBL9327376 | 0.94 | L3MBTL1 (0.62) | L3MBTL1CTSSCTSKCTSLCTSB | |
| SCHEMBL9327971 | 0.93 | L3MBTL1 (0.64) | L3MBTL1CTSSCTSKCTSLCTSB | |
| SCHEMBL9326780 | 0.93 | L3MBTL1 (0.64) | L3MBTL1CTSSCTSKCTSLCTSB | |
| SCHEMBL9437252 | 0.86 | L3MBTL1 (0.56) | L3MBTL1CTSSCTSKCTSLCTSB | |
| SCHEMBL9437260 | 0.86 | L3MBTL1 (0.56) | L3MBTL1CTSSCTSKCTSLCTSB | |
| SCHEMBL8899583 | 0.85 | L3MBTL1 (0.76) | L3MBTL1 | |
| SCHEMBL9781776 | 0.84 | L3MBTL1 (0.78) | L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025049746-A1 | COMPOSITIONS COMPRISING WERNER SYNDROME HELICASE INHIBITORS AND METHODS OF USING THE SAME | EIKON THERAPEUTICS, INC. (US) | 2025-03-06 | — | — | WO | disclosed |
| US-11149046-B2 | Antibacterial sideromycins | Hsiri Therapeutics, Inc. (US) | 2021-10-19 | — | — | US | disclosed |
| US-20190153010-A1 | ANTIBACTERIAL SIDEROMYCINS | Hsiri Therapeutics, LLC | 2019-05-23 | — | — | US | disclosed |
| US-7968553-B2 | e.g. N-(4-fluorobenzyl)-3-hydroxy-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; viricide in combination with other HIV/AIDS antivirals, immunomodulators, antibiotics or vaccines; AIDS | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2011-06-28 | — | — | US | disclosed |
| EP-1578748-B1 | TETRAHYDRO-4H-PYRIDO[1,2-A]PYRIMIDINES AND RELATED COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS | ANGELETTI P IST RICHERCHE BIO (IT) | 2010-09-15 | — | — | EP | disclosed |
| US-7414045-B2 | Substituted pyrimido[1,2-a]azepines useful as HIV integrase inhibitors | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2008-08-19 | — | — | US | disclosed |
| US-20080176869-A1 | Tetrahydro-4H-pyrido[1,2-a] pyrimidines useful as HIV integrase inhibitors | MSD ITALIA S.R.L. (IT) | 2008-07-24 | — | — | US | disclosed |
| US-20060046985-A1 | Tetrahydro--4h-pyrido[1,2-a}pyrimidines and related compounds useful as hiv integrase inhibitors | MSD ITALIA S.R.L. (IT) | 2006-03-02 | — | — | US | disclosed |
| EP-1578748-A1 | TETRAHYDRO-4H-PYRIDO [1, 2-A] PYRIMIDINES AND RELATED COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2005-09-28 | — | — | EP | disclosed |
| WO-2004058756-A1 | TETRAHYDRO-4H-PYRIDO[1,2-A]PYRIMIDINES AND RELATED COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2004-07-15 | — | — | WO | disclosed |
| WO-2004058757-A1 | TETRAHYDRO-4H-PYRIDO[1,2-A]PYRIMIDINES AND RELATED COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2004-07-15 | — | — | WO | disclosed |
| US-5367113-A | Iron chelate compounds with polyether derivatives | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 1994-11-22 | — | — | US | disclosed |
| US-5254724-A | Method for synthesis of desferrioxamine B, analogs and homologs thereof | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 1993-10-19 | — | — | US | disclosed |
| WO-1993009088-A1 | IMPROVED METHOD FOR SYNTHESIS OF DESFERRIOXAMINE B, ANALOGS AND HOMOLOGS THEREOF | UNIVERSITY OF FLORIDA (US) | 1993-05-13 | — | — | WO | disclosed |
| US-4987253-A | Method for the synthesis of desferrioxamine B and analogs thereof | UNIVERSITY OF FLORIDA (US) | 1991-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060046985-A1 | Tetrahydro--4h-pyrido[1,2-a}pyrimidines and related compounds useful as hiv integrase inhibitors | TYMS, TYMP, HPRT1 | L3MBTL1 1333/4885CTSS 3162/4885CTSK 3986/4885 |
| US-20080176869-A1 | Tetrahydro-4H-pyrido[1,2-a] pyrimidines useful as HIV integrase inhibitors | TYMS, TYMP, DPYD | L3MBTL1 1424/4885CTSS 2805/4885CTSK 3827/4885 |
| US-11149046-B2 | Antibacterial sideromycins | SLC40A1, SFXN1, SLC39A14 | L3MBTL1 1599/4885CTSS 502/4885CTSK 645/4885 |
| US-20190153010-A1 | ANTIBACTERIAL SIDEROMYCINS | SLC40A1, SFXN1, SLC39A14 | L3MBTL1 1599/4885CTSS 502/4885CTSK 645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.